Global Hormonal Contraceptive Market Size, Share, Growth, Trends, Company Analysis and Forecast 2019-2026

The global hormonal contraceptive market size is expected to reach USD 27.7 billion by 2026 and is estimated to expand at a CAGR of around 4.3% over the forecast period 2019 to 2026.

The major driving factors of the market growth are increase in focus towards family planning and need for preventing unintended pregnancy. The advancement in hormonal contraception with enhanced efficacy and fewer side effects are expected to further boost the market growth. Moreover, health issues associated with teenage pregnancies, increase in awareness towards modern contraception methods, and rise in use of oral pills as a key method to prevent unplanned pregnancy fuel the market growth. However, availability of alternate contraceptive methods, health risks associated with the use of contraceptives, and lack of social acceptance adversely affect the market growth.

Partnerships and collaborations for R&D activities and commercialization of new products are some of the key strategies adopted by the key players to increase their market share. For instance, Medicines 360 and Allergan announced partnership with health centers to help address unintended pregnancies in areas impacted by Zika, such as Puerto Rico and Florida, in February 2017. The partnership helped increase access to a hormonal contraceptive-Levonorgestrel-releasing Intrauterine System (LILETTA)-of the company in the region, which is indicated to prevent pregnancy for up to three years.

Further key findings from the report suggest: 

  • Increasing demand for contraceptive methods can be attributed to growing awareness about pills and devices, increasing significance of family planning, and supportive government regulations improving access to these products
  • In 2016, pills accounted for the largest share in the market as they are convenient to use and exhibit more than 99.0% effectivity when accurately consumed. Furthermore, ease of availability, fewer adverse effects, and large number of players operating in the market can be attributed to this share
  • The IUD segment is expected to witness the fastest growth during the forecast period. This can be attributed to entry of new devices in the market over the recent past, availability of long-acting reversible birth control methods, and more than 99.0% effectivity
  • Geographically, North America held the largest share in 2016 and is anticipated to maintain its dominance during the forecast period due to local presence of market players, high per capita income, and supportive government initiatives
  • Asia Pacific is estimated to witness the fastest growth during the forecast period due to high unmet need, expected increase in coverage during the next 15 years, and increasing number of women of reproductive age
  • Some of the key players operating in the market are Teva Pharmaceuticals Industries Ltd.; Bayer AG, Merck & Co. Inc.; Pfizer, Afaxys, Inc.; Agile Therapeutics; Allergan; and Apothecus Pharmaceutical Corporation.

Hormonal Contraceptive Market Key Segments:

By Product

  • Oral Contraceptive Pills
  • Injectable Birth Control
  • Emergency Contraceptive Pills
  • Vaginal Rings
  • Transdermal Patches

By Hormone

  • Progestin-only Contraceptive
  • Combined Hormonal Contraceptive

By Age Group

  • 15-24 Years
  • 25-34 Years
  • 35-44 Years
  • Above 44 Years

By End User

  • Hospitals
  • Household
  • Clinics

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Hormonal Contraceptive Market, By Method

7.1.  Hormonal Contraceptive Market, By Method, 2020-2028

7.1.1.    Pill

7.1.1.1.        Market Revenue and Forecast (2016-2028)

7.1.2.    Intrauterine Device (IUD)

7.1.2.1.        Market Revenue and Forecast (2016-2028)

7.1.3.    Injectable

7.1.3.1.        Market Revenue and Forecast (2016-2028)

7.1.4.    Vaginal Ring

7.1.4.1.        Market Revenue and Forecast (2016-2028)

7.1.5.    Implant

7.1.5.1.        Market Revenue and Forecast (2016-2028)

7.1.6.    Patch

7.1.6.1.        Market Revenue and Forecast (2016-2028)

Chapter 8.  Global Hormonal Contraceptive Market, Regional Estimates and Trend Forecast

8.1.  North America

8.1.1.    Market Revenue and Forecast, By Method (2016-2028)

8.1.2.    U.S.

8.1.3.    Rest of North America

8.1.3.1.        Market Revenue and Forecast, By Method (2016-2028)

8.2.  Europe

8.2.1.    Market Revenue and Forecast, By Method (2016-2028)

8.2.2.    UK

8.2.2.1.        Market Revenue and Forecast, By Method (2016-2028)

8.2.3.    France

8.2.3.1.        Market Revenue and Forecast, By Method (2016-2028)

8.2.4.    Rest of Europe

8.2.4.1.        Market Revenue and Forecast, By Method (2016-2028)

8.3.  APAC

8.3.1.    Market Revenue and Forecast, By Method (2016-2028)

8.3.2.    India

8.3.2.1.        Market Revenue and Forecast, By Method (2016-2028)

8.3.3.    China

8.3.3.1.        Market Revenue and Forecast, By Method (2016-2028)

8.3.4.    Japan

8.3.4.1.        Market Revenue and Forecast, By Method (2016-2028)

8.3.5.    Rest of APAC

8.3.5.1.        Market Revenue and Forecast, By Method (2016-2028)

8.4.  MEA

8.4.1.    Market Revenue and Forecast, By Method (2016-2028)

8.4.2.    GCC

8.4.2.1.        Market Revenue and Forecast, By Method (2016-2028)

8.4.3.    North Africa

8.4.3.1.        Market Revenue and Forecast, By Method (2016-2028)

8.4.4.    South Africa

8.4.4.1.        Market Revenue and Forecast, By Method (2016-2028)

8.4.5.    Rest of MEA

8.4.5.1.        Market Revenue and Forecast, By Method (2016-2028)

8.5.  Latin America

8.5.1.    Market Revenue and Forecast, By Method (2016-2028)

8.5.2.    Brazil

8.5.2.1.        Market Revenue and Forecast, By Method (2016-2028)

8.5.3.    Rest of LATAM

8.5.3.1.        Market Revenue and Forecast, By Method (2016-2028)

Chapter 9.    Company Profiles

9.1.  Allergan

9.1.1.    Company Overview

9.1.2.    Product Offerings

9.1.3.    Financial Performance

9.1.4.    Recent Initiatives

9.2.  Afaxys, Inc.

9.2.1.    Company Overview

9.2.2.    Product Offerings

9.2.3.    Financial Performance

9.2.4.    Recent Initiatives

9.3.  Teva Pharmaceuticals Industries Ltd.

9.3.1.    Company Overview

9.3.2.    Product Offerings

9.3.3.    Financial Performance

9.3.4.    Recent Initiatives

9.4.  Bayer AG

9.4.1.    Company Overview

9.4.2.    Product Offerings

9.4.3.    Financial Performance

9.4.4.    Recent Initiatives

9.5.  Merck & Co. Inc.

9.5.1.    Company Overview

9.5.2.    Product Offerings

9.5.3.    Financial Performance

9.5.4.    Recent Initiatives

9.6.  Pfizer

9.6.1.    Company Overview

9.6.2.    Product Offerings

9.6.3.    Financial Performance

9.6.4.    Recent Initiatives

9.7.  Agile Therapeutics

9.7.1.    Company Overview

9.7.2.    Product Offerings

9.7.3.    Financial Performance

9.7.4.    Recent Initiatives

9.8.  Apothecus Pharmaceutical Corporation

9.8.1.    Company Overview

9.8.2.    Product Offerings

9.8.3.    Financial Performance

9.8.4.    Recent Initiatives

Chapter 10.  Research Methodology

10.1.              Primary Research

10.2.              Secondary Research

10.3.              Assumptions

Chapter 11.  Appendix

11.1.              About Us

Glossary of Terms

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers
Ask to Expert